Tech Company Financing Transactions
Artielle ImmunoTherapeutics Funding Round
Sanderling Ventures, Northwest Technology Ventures and Pelion Venture Partners participated in a $11 million Series A funding round for Artielle ImmunoTherapeutics. The round was announced on 6/28/2006.
Transaction Overview
Company Name
Announced On
6/28/2006
Transaction Type
Venture Equity
Amount
$11,000,000
Round
Series A
Investors
Proceeds Purpose
The proceeds from the financing will be used over an estimated three-year period to complete pre-clinical trials, manufacture RTL1000 under current Good Manufacturing Practices (cGMPs), and to complete a Phase I human clinical trial and an initial Phase II trial. Of the $11 million funding commitment, $4 million was advanced in a first closing. The remaining $7 million will be advanced in two subsequent closings upon achievement of certain specified milestones.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7320 SW Hunziker Rd. 104
Tigard, OR 97223
USA
Tigard, OR 97223
USA
Phone
Website
Email Address
Overview
Artielle ImmunoTherapeutics develops recombinant T-cell receptor ligands to treat T-cell-mediated inflammatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Brock
Browse more venture capital transactions:
Prev: 6/28/2006: Cranite Systems venture capital transaction
Next: 6/29/2006: EPAC Technologies venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. All VC database entries on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs